Re: [Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial.
APA
Gómez Rivas J, Moreno Sierra J (2025). Re: [Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial.. European urology, 88(3), 308-309. https://doi.org/10.1016/j.eururo.2025.04.006
MLA
Gómez Rivas J, et al.. "Re: [Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial.." European urology, vol. 88, no. 3, 2025, pp. 308-309.
PMID
40268591
같은 제1저자의 인용 많은 논문 (4)
- The future of prostate cancer screening in the European Union: PRAISE-U project.
- Past and present of prostate cancer screening in the European Union.
- Re: Darolutamide in Combination with Androgen-deprivation Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer from the Phase III ARANOTE Trial.
- Research protocol for the evaluation of TriNetra™ prostate: a circulating tumor cell-based diagnostic tool for prostate cancer.